Mineralys Therapeutics, Inc. (MLYS) Stock Statistics & Valuation Metrics

Mineralys Therapeutics, Inc. has a market cap or net worth of $1.61B. The enterprise value is $1.72B.

Market Cap

$1.61B

Enterprise Value

$1.72B

Mineralys Therapeutics, Inc. has 88,406,880 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

88,406,880

Owned by Insiders

25.20%

Owned by Institutions

42.80%

Mineralys Therapeutics, Inc.’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -26.38%.

Return on Equity (ROE)

-0.24

Return on Assets (ROA)

-0.23

Return on Invested Capital (ROIC)

-26.38%

Return on Capital Employed (ROCE)

-0.26

Revenue Per Employee

0

Profits Per Employee

-2.03M

Employee Count

76

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Mineralys Therapeutics, Inc. is -3.67. Mineralys Therapeutics, Inc.’s PEG ratio is 0.03.

PE Ratio

-3.67

PS Ratio

0.00

PB Ratio

2.39

Price to FCF

-9.90

Price to Operating Cash Flow

-9.49

PEG Ratio

0.03

In the last 12 months, Mineralys Therapeutics, Inc. had revenue of 0 and earned -154.65M in profits. Earnings per share was -2.29.

Revenue

0

Gross Profit

0

Operating Income

-170.60M

Pretax Income

-154.65M

Net Income

-154.65M

EBITDA

-154.59M

Earnings Per Share (EPS)

-2.29

In the last 12 months, operating cash flow was -138.79M and capital expenditures -15,000, giving a free cash flow of -138.80M billion.

Operating Cash Flow

-138.79M

Free Cash Flow

-138.80M

Free Cash Flow per Share

-1.64

Mineralys Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-10.11%

Earnings Yield

-26.57%

Beta

1.37

52-Week Price Change

-61.94%

50-Day Moving Average

24.83

200-Day Moving Average

26.91

Relative Strength Index (RSI)

23.79

Average Volume (3m)

1.33M

Mineralys Therapeutics, Inc. upcoming earnings date is Nov 04, 2026, After Close (Not Confirmed).

Last Earnings Date

Aug 11, 2026

Next Earnings Date

Nov 04, 2026

Ex-Dividend Date

―

Mineralys Therapeutics, Inc. as a current ratio of 43.76, with Debt / Equity ratio of 0.00%

Current Ratio

43.76

Quick Ratio

43.76

Debt to Market Cap

0.00

Net Debt to EBITDA

1.12

Interest Coverage Ratio

0.00

In the past 12 months, Mineralys Therapeutics, Inc. has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Mineralys Therapeutics, Inc. EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -9.60.

EV to Sales

0.00

EV to EBITDA

-3.81

EV to Free Cash Flow

-9.60

EV to Operating Cash Flow

-9.60

Mineralys Therapeutics, Inc. has $661.41M in cash and marketable securities with $97.62M in debt, giving a net cash position of $563.79M billion.

Cash & Marketable Securities

$661.41M

Total Debt

$97.62M

Net Cash

$563.79M

Net Cash Per Share

$6.38

Tangible Book Value Per Share

$6.50

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Mineralys Therapeutics, Inc. is $47.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$47.86

Price Target Upside

207.76% Upside

Analyst Consensus

Strong Buy

Analyst Count

7

Revenue Growth Forecast

―

EPS Growth Forecast

-19.00%

Smart Score

5

AI Score

51